Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGM-719
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
01
Overview
AGM-719 (also referred to as AMG 719) is an investigational drug that was studied for the treatment of rheumatoid arthritis. It was evaluated in a multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 clinical trial in patients with rheumatoid arthritis who were also receiving methotrexate. The study aimed to assess the efficacy, safety, and tolerability of AGM-719 in this patient population. The developer and primary sponsor for the clinical trial was Amgen[1].
- Other names
- AGM 719AGM719AGM-719AMG 719AMG719AMG-719
Beyond the preview
Go deeper on AGM-719.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGM-719.